Clinical trial • Phase II • Cardiology

LEVOSIMENDAN for Cardiogenic shock

Phase II trial of LEVOSIMENDAN for Cardiogenic shock.

Overview

Trial Therapeutic Area
Cardiology
Trial Disease
Cardiogenic shock
Trial Stage
Phase II
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
02-11-2023
First CTIS Authorization Date
11-03-2024

Trial design

Randomised, placebo: cernevit (pulver zur herstellung einer injektions- oder einer infusionslösung) administered as infusion (placebo comparator).-controlled Phase II trial across 1 site in Austria.

Randomised
Yes
Comparator
Placebo: Cernevit (pulver zur Herstellung einer Injektions- oder einer Infusionslösung) administered as infusion (placebo comparator).
Target Sample Size
46
Trial Duration For Participant
28

Eligibility

Recruits 46 Vulnerable population selected (isVulnerablePopulationSelected=true); no information provided on consent or assent procedures for vulnerable participants..

Pregnancy Exclusion
• Pregnant women
Vulnerable Population
Vulnerable population selected (isVulnerablePopulationSelected=true); no information provided on consent or assent procedures for vulnerable participants.

Inclusion criteria

  • {"criterion_text":"- Age ≥ 18 years\n- Undergoing ECMO for cardiogenic shock or refractory cardiac arrest"}

Exclusion criteria

  • {"criterion_text":"- Coma with fixed dilatation of pupils that was not induced by drugs or other circumstances indicating likely futility\n- Mechanical cause of cardiogenic shock (e.g., ventricular septal defect or papillary muscle rupture)\n- Onset of shock more than 12 hours before screening\n- Massive pulmonary embolism\n- Severe peripheral arterial disease precluding insertion of ECMO cannula\n- Aortic regurgitation greater than grade II in severity (on a scale of I to IV, with higher grades indicating more severe regurgitation)\n- Age > 90 years\n- Severe concomitant disease associated with a life expectancy of less than 6 months\n- Pregnant women"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- \tChange in left ventricular outflow tract velocity time integral measured by Doppler echocardiography from baseline to 72h after initiation ECMO or before cessation of ECMO support, whichever occurs first","definition_or_measurement_approach":"Measured by Doppler echocardiography: change in left ventricular outflow tract velocity time integral from baseline to 72 hours after ECMO initiation or before cessation of ECMO support, whichever occurs first."}

Secondary endpoints

  • {"endpoint_text":"- Change in pulse pressure from baseline to 72h after initiation of ECMO or before cessation of ECMO support, whichever occurs first\n- ECMO weaning failure, defined as death during ECMO support, death within 24 h after ECMO removal or need for reimplantation of ECMO within 24 h.\n- All cause mortality at 28 days\n- Urinary output for the first 48 hours post cessation of ECMO support\n- Central venous saturation at 4, 8, 12, 24 and 48 hours post cessation of ECMO support\n- Total days requiring ECMO","definition_or_measurement_approach":"Change in pulse pressure: from baseline to 72h after ECMO initiation or before cessation. ECMO weaning failure: defined as death during ECMO support, death within 24 h after ECMO removal or need for reimplantation within 24 h. All-cause mortality assessed at 28 days. Urinary output measured for first 48 hours post cessation. Central venous saturation measured at specified timepoints (4,8,12,24,48 hours). Total days requiring ECMO recorded as days."}

Recruitment

Planned Sample Size
46
Recruitment Window Months
12

Geography

Total Number Of Sites
1
Total Number Of Participants
46

Austria

Earliest CTIS Part Ii Submission Date
29-02-2024
Latest Decision Or Authorization Date
11-03-2024
Processing Time Days
11
Number Of Sites
1
Number Of Participants
46

Sites

Site Name
Medical University Of Vienna
Department Name
Department of Internal Medicine II, Division of Cardiology
Principal Investigator Name
Robert Zilberszac
Principal Investigator Email
robert.zilberszac@meduniwien.ac.at
Contact Person Name
Robert Zilberszac

Sponsor

Primary sponsor

Full Name
Allgemeines Krankenhaus Der Stadt Wien Universitatskliniken
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Austria

Co-sponsors

  • Medical University Of Vienna

Investigational products

Investigational Product Name
Levosimendan EQL Pharma 2,5mg/ml Konzentrat zur Herstellung einer Infusionslösung
Active Substance
LEVOSIMENDAN
Modality
Small molecule
Routes Of Administration
Infusion
Route
Infusion
Authorisation Status
Authorised in AT (marketing authorisation number 141525)
Maximum Dose
12.5 mg
Investigational Product Name
Cernevit, Pulver zur Herstellung einer Injektions- oder einer Infusionslösung
Active Substance
Retinol palmitate; Ascorbic acid; Colecalciferol; Cyanocobalamin; Dexpanthenol; Folic acid; Nicotinamide; Pyridoxine hydrochloride; Riboflavin sodium phosphate dihydrate; D-biotin; DL-alpha-tocopherol; Cocarboxylase tetrahydrate
Modality
Small molecule
Routes Of Administration
Infusion
Route
Infusion
Authorisation Status
Authorised in BE (marketing authorisation number BE152223)
Maximum Dose
1 U unit(s)

Related trials

Other published trials that may interest you.